Today, with a net worth of roughly $400 million accrued through various enterprises, Angermayer is one of the driving forces behind the movement to turn long-shunned psychoactive substances, like the psilocybin derived from so-called magic mushrooms, into approved medications for depression and other mental illnesses.

The strangest and most daring idea mentioned in the Scientific American piece by Meghana Keshavan relates to a bizarre project for resolving the Israeli-Palestinian conflict:

But their talk shifted to one of the highest priority projects at the nonprofit: An exploration of psychedelics in conflict remediation. Along with researchers at Imperial College London, MAPS plans on bringing Israelis and Palestinians together to take ayahuasca and, working with negotiation experts, sift through their respective traumas. The idea is that finding common ground in their spiritual and mystical experiences might help coax political reconciliation between the warring factions.

The researchers found that people who regularly take selfies thought that they looked more attractive and likable in their selfies than in the photographs taken by an experimenter. Other observers, however, rated them as less likable and more narcissistic in their selfies as compared with the nonselfies.